CPA
URGN icon

Capital Performance Advisors’s UroGen Pharma URGN Stock Holding History

Capital Performance Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-138
Closed -$1.75K – 2560
2024
Q3 		$1.75K Buy
+138
New +$2.05K ﹤0.01% 1627

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital Performance Advisors's URGN Position: Q4 2024 in Review

Capital Performance Advisors sold out of UroGen Pharma (URGN) in Q4 2024, closing a stake of 138 shares — an estimated $1.75K sold.

Capital Performance Advisors first reported a position in URGN in Q3 2024 and held it in 1 quarter. The position peaked at $1.75K in Q3 2024. 138 funds tracked by Wall St. Rank hold URGN as of Q4 2024.

  • Capital Performance Advisors reported no remaining UroGen Pharma position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 138 UroGen Pharma shares in Q4 2024, an estimated $1.75K.
  • Capital Performance Advisors first reported a position in UroGen Pharma in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's UroGen Pharma position peaked at $1.75K in Q3 2024.
  • 138 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.